外源性库欣综合征的死亡风险与死因:系统综述与荟萃分析
汇总SMR为1.87(95%CI 1.32-2.61),累计剂量≥5 g泼尼松等效、平均日剂量>5 mg/天及较高初始剂量均与死亡风险升高独立相关;心血管疾病为首位死因。
要点
- 长期口服GC暴露者汇总SMR 1.87,全因死亡风险升高。
- 累计剂量≥5 g泼尼松等效及日剂量>5 mg/天与死亡风险升高相关。
- 心血管疾病为首位死因,其次为恶性肿瘤和感染。
核心结论
- 慢性口服糖皮质激素暴露与多疾病组死亡风险升高相关。
- 较高的累计剂量和早期治疗剂量与更高死亡风险相关。
- 因果归因仍不确定,受适应证混杂、疾病严重度数据有限和暴露错分影响。
- 结果支持糖皮质激素规范管理及针对心血管和感染风险的干预,而非不加区分地减量。
研究设计与样本
- 系统综述与荟萃分析,遵循PRISMA指南(PROSPERO CRD42017067530)。
- 检索PubMed/MEDLINE、EMBASE、Cochrane Library、Web of Science和CINAHL,时间1945年至2019年3月。
- 纳入报告标准化死亡比(SMR)或绝对死亡数的成人慢性口服GC研究。
- 采用随机效应荟萃分析和混合效应荟萃回归合成死亡率及剂量反应关联。
主要发现
- 慢性GC暴露与超额死亡相关,汇总SMR 1.87(95%CI 1.32-2.61;I2 74.0%)。
- 汇总死亡比例为12.0%(95%CI 10-14%)。
- 炎症性疾病死亡风险最高(30.0%),血管炎为18.0%。
- 心血管疾病为首位死因(25.6%),其次为恶性肿瘤(15.7%)和感染(13.4%)。
- 较高累计剂量(≥5 g泼尼松等效)、平均日剂量>5 mg/天和较高初始剂量均与死亡风险升高独立相关。
关键数值与推荐
- 汇总SMR 1.87(95%CI 1.32-2.61;I2 74.0%)。
- 汇总死亡比例12.0%(95%CI 10-14%)。
- 炎症性疾病死亡比例30.0%,血管炎18.0%。
- 心血管疾病死因占25.6%,恶性肿瘤15.7%,感染13.4%。
- 累计剂量≥5 g泼尼松等效、平均日剂量>5 mg/天与死亡风险升高相关。
临床怎么用
- 对长期口服GC患者应评估并管理心血管疾病和感染风险。
- 关注累计剂量和初始高剂量,推行糖皮质激素规范管理。
- 不宜不加区分地减量,应结合适应证和疾病严重度个体化决策。
局限性
- 适应证混杂可能影响因果归因。
- 疾病严重度数据有限。
- 存在暴露错分类。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Chronic oral glucocorticoids (GCs) are widely prescribed for multiple diseases. Although long-term GC exposure causes systemic toxicity, the magnitude, dose-response relationship, and causes of GC-associated mortality remain incompletely defined. OBJECTIVE: To quantify overall and cause-specific mortality associated with chronic oral GC exposure and evaluate dose-response relationships across underlying disease groups. METHODS: We conducted a systematic review and meta-analysis following PRISMA guidelines (PROSPERO CRD42017067530). PubMed/MEDLINE, EMBASE, Cochrane Library, Web of Science, and CINAHL were searched from 1945 to March 2019. Eligible studies reported standardized mortality ratios (SMRs) or absolute deaths among adults receiving chronic oral GCs. Random-effects meta-analysis and mixed-effects meta-regression were used to synthesize mortality and dose-response associations across GC exposure metrics, exposure duration, and disease subgroups. RESULTS: One-hundred and sixteen studies encompassing 128 cohorts and 51 380 patients were included. Chronic GC exposure was associated with excess mortality (pooled SMR 1.87; 95%CI 1.32-2.61; I2 74.0%). The pooled proportion of death was 12.0% (95%CI 10-14%). Mortality risk was highest in inflammatory diseases (30.0%) and the vasculitides (18.0%). Higher cumulative dose (≥5 g prednisolone-equivalent), average daily dose >5 mg/day, and higher initial dose were each independently associated with increased mortality. Cardiovascular disease was the leading causes of death (25.6%), followed by malignancy (15.7%) and infection (13.4%). CONCLUSION: Chronic oral GC exposure was associated with increased mortality across disease groups, with higher cumulative and early-treatment doses correlating with higher risk. However, causal attribution remains uncertain due to confounding by indication, limited disease-severity data, and exposure misclassification. These findings support GC stewardship and targeted cardiovascular and infection risk mitigation, rather than indiscriminate dose reduction.
引用
- Limumpornpetch P, Stewart PM, Pujades-Rodriguez M, et al. Mortality risk and causes of death in exogenous Cushing's syndrome: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2026. PMID: 41873700. doi:10.1210/clinem/dgag123
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。